Article
Detection and molecular characterization of the novel recombinant norovirus GII.P16-GII.4 Sydney in southeastern Brazil in 2016
Registro en:
BARREIRA, Débora Maria Pires Gonçalves et al. Detection and molecular characterization of the novel recombinant norovirus GII.P16-GII.4 Sydney in southeastern Brazil in 2016. Plos One, p. 1-9, Dec. 2017.
1932-6203
10.1371/journal.pone.0189504
1932-6203
Autor
Barreira, Débora Maria Pires Gonçalves
Fumian, Túlio Machado
Tonini, Marco André Loureiro
Volpini, Lays Paula Bondi
Santos, Rodrigo Pratte
Ribeiro, Anézia Lima Chaves
Leite, José Paulo Gagliardi
Souza, Márcia Terezinha Baroni de Moraes e
Brasil, Patrícia
Cunha, Denise Cotrim da
Miagostovich, Marize Pereira
Spano, Liliana Cruz
Resumen
Noroviruses are the leading cause of acute gastroenteritis (AGE) in all age groups worldwide. Despite the high genetic diversity of noroviruses, most AGE outbreaks are caused by a single norovirus genotype: GII.4. Since 1995, several different variants of norovirus GII.4 have been associated with pandemics, with each variant circulating for 3 to 8 years. The Sydney_2012 variant was first reported in Australia and then in other countries. A new variant, GII.P16-GII.4, was recently described in Japan and South Korea and then in the USA, France, Germany and England. In our study, 190 faecal specimens were collected from children admitted to a paediatric hospital and a public health facility during a surveillance study of sporadic cases of AGE conducted between January 2015 and July 2016. The norovirus was detected by RT-qPCR in 51 samples (26.8%), and in 37 of them (72.5%), the ORF1-2 junction was successfully sequenced. The new recombinant GII.P16-GII.4 Sydney was revealed for the first time in Brazil in 2016 and predominated among other strains (9 GII.Pe-GII.4, 3 GII.P17-GII.17, 1 GII.Pg-GII.1, 1 GII.P16-GII.3 and 1 GII.PNA-GII.4). The epidemiological significance of this new recombinant is still unknown, but continuous surveillance studies may evaluate its impact on the population, its potential to replace the first recombinant GII.Pe-GII.4 Sydney 2012 variant, and the emergence of new recombinant forms of GII.P16.